Michael Schubert will be responsible for the management of research and development activities worldwide, including the United States, Germany, Switzerland and Japan
Bruker Daltonics announces that Michael Schubert has been appointed as vice president for research and development.
Bruker Daltonics says its business has more than tripled in the past five years, based on innovative, high-quality products, and a strong commitment to customer service and support.
Dr Schubert will be responsible for the management of the company's research and development activities worldwide, including R and D activities in the United States, Germany, Switzerland and Japan. In 1992, Michael Schubert received his doctorate from the University of Hamburg in physics.
From 1991 to 2000, he was project manager in the Bruker Daltonics ion trap programme.
In 2000, he became responsible for the company's R and D activities in Bremen, Germany, and since August 2002, he has also served as managing director of Bruker Daltonik, located in Bremen and Leipzig, Germany.
Frank Laukien, president and CEO of Bruker Daltonics, stated: "We are very pleased to have Michael assume this new global R and D position to address the present and future needs of our pharmaceutical, biotech, diagnostics and other life-science customers, as well as our security and defense customers.
"Michael will drive our development of innovative applications-driven solutions and robust easy-to-use systems for automated routine analysis.
"He understands our technology base and markets very well, and brings a wealth of experience in managing internal R and D and strategic collaborations". "I am looking forward to leading our global R and D efforts at such an exciting time in the growth of life-science applications of mass spectrometry," commented Schubert. "Driving sample preparation, consumables, instrument and bioinformatics development for comprehensive applications-oriented solutions offers many great opportunities. "We will use our resources and strategic partnerships to offer systems and solutions for expression proteomics, clinical proteomics and metabonomics applied to drug discovery and development, as well as to clinical and academic research. "A special R and D focus will also be on advanced chemical and biological detection systems for homeland security and defense."
